Isofol Medical Q3’20: AGENT Enrolment is Still Brisk
Redeye is encouraged by the excellent progress in the recruitment for the AGENT trial during Q3. The upfront payment from the Solasia deal was lower than we had expected; however, Solasia will assume costs for the expansion of the trial in Japan. We reiterate our base case.